PRESS RELEASE published on 02/06/2024 at 16:00, 1 year 10 months ago Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease Cantabio Pharmaceuticals, Inc. receives major grant from MJFF for the development of DJ-1 replacement therapy aimed at treating Parkinson's disease by increasing DJ-1 levels in patients and preventing disease progression Precision Medicine Cantabio Pharmaceuticals MJFF Grant DJ-1 Replacement Therapy Parkinson's Disease
Published on 12/18/2025 at 15:00, 3 hours 27 minutes ago Vox Royalty Acquires Feasibilty-Stage Stockman Copper-Gold Royalty in Australia
Published on 12/18/2025 at 14:31, 3 hours 56 minutes ago Worksport Reports Highest Monthly Revenue in Company History
Published on 12/18/2025 at 14:00, 4 hours 27 minutes ago Route1 Announces Provisional Patent Application
Published on 12/18/2025 at 14:00, 4 hours 27 minutes ago LQR House Announces $6.52 Million Registered Direct Offering
Published on 12/18/2025 at 18:00, 27 minutes ago Wicomico County Selects Waga Energy to Upgrade Landfill Gas to RNG in Maryland
Published on 12/18/2025 at 17:45, 42 minutes ago ENOGIA: ENOGIA selected to supply South Korea’s first fully privately financed waste-heat-to-power project on a fuel cell plant
Published on 12/18/2025 at 17:40, 47 minutes ago LIGHTON: Information concerning the total number of voting rights and shares in the share capital as of 30 november 2025.
Published on 12/18/2025 at 17:40, 47 minutes ago VALBIOTIS SA: Valbiotis recognized by the 2025 Top Santé Award for Valbiotis Plus® Serenity, an innovative solution for emotional balance
Published on 12/18/2025 at 16:31, 1 hour 56 minutes ago In Brazil, ENGIE Fully Commissions Serra do Assuruá, Its Largest Wind Complex Worldwide
Published on 12/17/2025 at 20:39, 21 hours 48 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 18:00, 1 day ago Outstanding Shares and Voting Rights Statement at 30 November 2025